We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. atai Life Sciences N.V. (ATAI - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
atai Life Sciences N.V. is one of 972 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. atai Life Sciences N.V. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATAI's full-year earnings has moved 16.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ATAI has returned about 254.9% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.6%. This means that atai Life Sciences N.V. is performing better than its sector in terms of year-to-date returns.
Halozyme Therapeutics (HALO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 60.4%.
Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 14.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, atai Life Sciences N.V. belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 15 individual companies and currently sits at #70 in the Zacks Industry Rank. On average, stocks in this group have gained 9.9% this year, meaning that ATAI is performing better in terms of year-to-date returns.
On the other hand, Halozyme Therapeutics belongs to the Medical - Biomedical and Genetics industry. This 483-stock industry is currently ranked #99. The industry has moved +4.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to atai Life Sciences N.V. and Halozyme Therapeutics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. atai Life Sciences N.V. (ATAI - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
atai Life Sciences N.V. is one of 972 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. atai Life Sciences N.V. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATAI's full-year earnings has moved 16.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ATAI has returned about 254.9% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.6%. This means that atai Life Sciences N.V. is performing better than its sector in terms of year-to-date returns.
Halozyme Therapeutics (HALO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 60.4%.
Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 14.2%. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, atai Life Sciences N.V. belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 15 individual companies and currently sits at #70 in the Zacks Industry Rank. On average, stocks in this group have gained 9.9% this year, meaning that ATAI is performing better in terms of year-to-date returns.
On the other hand, Halozyme Therapeutics belongs to the Medical - Biomedical and Genetics industry. This 483-stock industry is currently ranked #99. The industry has moved +4.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to atai Life Sciences N.V. and Halozyme Therapeutics as they could maintain their solid performance.